【盈警】泰凌医药(01011.HK)料2025年公司拥有人应占亏损同比减少43.8%至53.2%

Core Viewpoint - The company expects to report a net loss attributable to shareholders of approximately 25 million to 30 million RMB for the fiscal year ending December 31, 2025, representing a decrease of about 43.8% to 53.2% compared to the same period in 2024 [1] Summary by Relevant Categories Financial Performance - The anticipated reduction in loss is primarily due to the absence of a one-time non-cash fair value loss of approximately 29.5 million RMB related to the equity of Beijing Kangchen Biotechnology Co., Ltd. recognized in the previous year [1] - The company expects to record a fair value gain of approximately 14 million RMB on financial assets (specifically the aforementioned equity) in the current fiscal year [1]